On 26 June 2018, Aptahem (publ) signed an issuance agreement with YA II PN Ltd, a fund represented by the United States-based Yorkville Advisors Global (“Yorkville”), which describes the terms of issuance of and subscription to notes convertible into...
Read MoreAptahem AB (publ), a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved in the disease process, today announce its entry into an issuance agreement with...
Read MoreAptahem AB (publ) announces a partnership with Seattle Children’s Research Institute to explore the mechanisms underlying their new aptamer-based therapeutic for acute and chronic inflammatory conditions including sepsis. Sepsis is a complex and potentially life-threatening condition that occurs when...
Read MoreAptahem AB (publ.), a biotech company that develops aptamer-based drugs for the treatment of life-threatening conditions in which coagulation and inflammation interact in the disease process, can today announce that it will start its first toxicology trials this week....
Read MoreThe 5 May each year is announced the Clean Your Hands Day by the WHO to raise the awareness and prevent sepsis around the world, specifically in the health care sector. Take part of the information and campaign or watch...
Read MoreCEO comments It’s scarcely a month since our previous newsletter, but so much is happening at the moment that I wanted to give you an update on our activities earlier than planned. In this extra edition of the newsletter,...
Read MoreCEO comments 2018 is very much underway, and we’re really building momentum – what a start to the year we’ve had! So much has happened in the barely three months since the beginning of the year, and I look...
Read MoreAptahem AB (publ) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved in the disease process. Aptahem is today pleased to announce the appointment...
Read MoreAptahem AB (Aktietorget: APTA) a biotechnology company which is developing aptamer-based drugs for the treatment of life-threatening conditions in which coagulation and inflammation work together in the disease process, announces that production process of the company´s drug candidate Apta-1...
Read MoreAptahem is today pleased to announce the recruitment to the company´s scientific advisory board of Hans Peter Schwarz and Mats Eriksson; two highly experienced and internationally recognised experts. Professor Hans Peter Schwarz, MD has previously held leading positions within...
Read More